Literature DB >> 27134147

Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis.

F Coccolini1, F Catena2, O Glehen3, Y Yonemura4, P H Sugarbaker5, P Piso6, M Ceresoli7, G Montori7, L Ansaloni7.   

Abstract

INTRODUCTION: The most common cause of tumour progression in advanced gastric cancer is peritoneal carcinosis (PC). The necessity to increase the survival in advanced diseases suggested to deliver the chemotherapy directly in the peritoneal cavity also in Cy+/PC- and to experiment the effect of massive peritoneal lavage to wash out the tumour cells. The aim of this study is to investigate the gain in term of survival and peritoneal recurrence rate of the intraperitoneal chemotherapy and/or peritoneal lavage in patients with Cy+/PC-.
MATERIAL AND METHODS: A systematic review with meta-analysis of trials about the effect of intraperitoneal chemotherapy (IPC) and/or peritoneal lavage (PL) on positive cytology in gastric cancer without carcinosis.
RESULTS: Three trials have been included (164 patients: 76 received surgery alone, 51 surgery + IPC and 37 surgery + IPC + PL). Two- and five-years survival is increased by IPC (RR = 1.62, RR = 3.10). 2 and 5 years survival is further increased by IPC + PL (RR = 2.33, RR = 6.19). Peritoneal recurrence is reduced by IPC (OR = 0.45) and by IPC + PL (OR = 0.13).
CONCLUSIONS: Two- and five-years overall survival in patients with free cancer cells without carcinosis is incremented by intraperitoneal chemotherapy. Peritoneal lavage further increases these survival rates and also it further decreases the peritoneal recurrence rate.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytoreduction; Gastric cancer; Intraperitoneal chemotherapy; Meta-analysis; Mortality; Positive cytology; Surgery; Survival

Mesh:

Substances:

Year:  2016        PMID: 27134147     DOI: 10.1016/j.ejso.2016.03.035

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

1.  Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis.

Authors:  Paola Fugazzola; Federico Coccolini; Giulia Montori; Marco Ceresoli; Paolo Baggi; Antonio Costanzo; Matteo Tomasoni; Francesco Gregis; Silvia Nozza; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 2.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

3.  Intraperitoneal administration of nanoparticles containing tocopheryl succinate prevents peritoneal dissemination.

Authors:  Susumu Hama; Takayuki Nishi; Eitaro Isono; Shoko Itakura; Yutaka Yoshikawa; Akinori Nishimoto; Satoko Suzuki; Naoko Kirimura; Hiroaki Todo; Kentaro Kogure
Journal:  Cancer Sci       Date:  2022-03-31       Impact factor: 6.518

4.  The importance of primary tumor origin in gastrointestinal malignancies undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Natasha Leigh; Daniel Solomon; Eric Pletcher; Daniel M Labow; Deepa R Magge; Umut Sarpel; Benjamin J Golas
Journal:  World J Surg Oncol       Date:  2020-07-23       Impact factor: 2.754

5.  Mixed lineage kinase-4 promotes gastric carcinoma tumorigenesis through suppression of the c-Jun N-terminal kinase signaling pathway.

Authors:  Yu Xi; Jianhua Niu; Dongmei Li; Jiagen He; Le Qin; Xinyu Peng
Journal:  Exp Ther Med       Date:  2018-08-20       Impact factor: 2.447

Review 6.  Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy.

Authors:  Federico Coccolini; Paola Fugazzola; Luca Ansaloni; Massimo Sartelli; Enrico Cicuttin; Gioacchino Leandro; Gian Luigi De' Angelis; Federica Gaiani; Francesco Di Mario; Matteo Tomasoni; Fausto Catena
Journal:  Acta Biomed       Date:  2018-12-17

7.  Multi-Modality Treatment for Patients With Metastatic Gastric Cancer: A Real-World Study in China.

Authors:  Lin Zhao; Jiarui Li; Chunmei Bai; Yongdu Nie; Guole Lin
Journal:  Front Oncol       Date:  2019-11-01       Impact factor: 6.244

8.  Survival outcomes and prognostic indicators for gastric cancer patients with positive peritoneal wash cytology but no peritoneal metastasis after radical gastrectomy.

Authors:  Wen-Zhe Kang; Yu-Xin Zhong; Fu-Hai Ma; Li-Yan Xue; Jian-Ping Xiong; Shuai Ma; Yang Li; Yi-Bin Xie; Xu Quan; Yan-Tao Tian
Journal:  World J Gastrointest Oncol       Date:  2021-01-15

9.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian and gastrointestinal peritoneal carcinomatosis: results from a 7-year experience.

Authors:  Giulia Montori; Federico Coccolini; Paola Fugazzola; Marco Ceresoli; Matteo Tomasoni; Carolina Rubicondo; Stefano Raimondo; Domenico Pinelli; Michele Colledan; Luigi Frigerio; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2018-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.